In this talk, I will explore the impact of low-frequency mutations on the evolution of drug-resistant HIV, highlighting our breakthroughs with the AMPHEUS system and veSEQ pipeline for advanced genomic analyses. Our findings reveal crucial insights into the underestimated prevalence of transmitted NRTI resistance, underscoring the urgent need for enhanced surveillance in areas with high treatment failure rates.

David Bonsall, is a pioneer of pathogen genomics, leads efforts to unravel the complexities of drug resistant in HIV, leveraging cutting-edge technologies to inform global health strategies.